摘要
目的观察替莫唑胺治疗恶性难治性胶质瘤的疗效及安全性。方法10例恶性难治性胶质瘤患者给予替莫唑胺150～200mg/m2,连续空腹口服5d,每4周重复。所有患者至少接受两个疗程化疗。结果化疗后进行脑MRI复查,比较MRI结果判断疗效:肿瘤体积明显缩小者2例,部分缓解率20%;肿瘤无进展时间超过12周者3例,疾病稳定率30%;症状缓解4例,症状缓解率40%;总显效率50%。替莫唑胺主要不良反应为恶心、呕吐、脱发、疲倦和骨髓抑制等,程度较轻,未见重要脏器损害。结论替莫唑胺对恶性难治性胶质瘤具有较好的临床效果,不良反应较少,是理想的化疗用药。
Objective To evaluate the efficacy and side effects of temozolomide in the treatment of refractory malignant gliomas. Methods Ten patients with refractory malignant gliomas were treated with temozolomide once daily for 5 days and 28 days as a treatment course. All the patients received at least 2 cycles of the treatment. Results Confirmed by the MRI examination after chemotherapy, the partial response （PR） rate was 20% （2/10） in this group. Three patients （30%） showed stable disease （SD） more than 12 weeks. The symptom release rate was 40% （4/10）. The major toxicity of temozolomide included nausea,vomiting, losing hair, tiredness and inhibition of the marrow. There was no severe side effect found in these patients. Conclusion Temozolomide is an effective and tolerable regimen for refractory malignant gliomas with low incidence of adverse effects.
出处
《中国实用神经疾病杂志》
2009年第13期33-35,共3页
Chinese Journal of Practical Nervous Diseases
关键词
替莫唑胺
胶质瘤
化疗
Temozolomide
Glioma
Chemotherapy
